cephalosporin c has been researched along with piperacillin, tazobactam drug combination in 138 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.17) | 18.2507 |
| 2000's | 27 (19.57) | 29.6817 |
| 2010's | 82 (59.42) | 24.3611 |
| 2020's | 26 (18.84) | 2.80 |
| Authors | Studies |
|---|---|
| Bonomo, RA; Carias, LL; Rice, LB; Shlaes, DM | 1 |
| Brière, S; Brun-Buisson, C; Petit, C; Schweich, H; Sollet, JP | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Alvarez-Lerma, F; Barcenilla, F; Insausti-Ordeñana, J; Jordá-Marcos, R; Maraví-Poma, E; Martínez-Pellús, A; Nava, J; Palomar, M; Torres-Martí, A | 1 |
| Powell, LL; Wilson, SE | 1 |
| Ambrose, PG; Bhavnani, SM; Jones, RN | 1 |
| Charlett, A; Henwood, CJ; James, D; Johnson, AP; Livermore, DM; Mushtaq, S; Potz, N; Walker, RA; Warburton, F; Warner, M | 1 |
| Ceran, N; Erdem, I; Kucukercan, M | 1 |
| Arango, C; Bantar, C; Coassolo, MA; Duret, F; Fiorillo, A; Franco, D; Gomez, H; Heft, C; Krayeski, M; Oliva, ME; Salamone, F; Vesco, E | 1 |
| Brown, A; Corrado, O; Donaldson, K; Fawley, W; Freeman, J; MacKinlay, S; Wilcox, MH | 1 |
| Burgess, DS; Frei, CR | 1 |
| Burgess, DS; Frei, CR; Reese, AM | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Greenberg, A; Muallem-Zilcha, E; Raveh, D; Schlesinger, Y; Wiener-Well, Y; Yinnon, AM | 1 |
| Bow, EJ; Laverdiere, M; Noskin, GA; Rotstein, C; Sanche, S; Schwarer, AP; Segal, BH; Seymour, JF; Szer, J | 1 |
| Chun, BC; Jeong, HW; Kim, MJ; Park, DW; Sohn, JW; Yang, JA | 1 |
| Gurkan, E; Hutton-Thomas, R; Lakticová, V; Meyer, M; Rice, LB | 1 |
| Agarwal, N; Agarwal, S; Arya, SC | 1 |
| de Cueto, M; Hernández, JR; Muniain, MA; Navarro, MD; Pascual, A; Ríos, MJ; Rodríguez-Baño, J; Romero, L | 1 |
| Fritsche, TR; Hsiung, A; Jones, RN; Sader, HS | 1 |
| Araujo, VR; Carvalho-Dias, VM; Cunha, CA; de Souza, CA; de Souza, M; Godoy, C; Lotfi, CJ; Maiolino, A; Nucci, M; Oliveira, AL; Pasquini, R; Ruiz, MA; Seber, A; Silla, L; Simões, BP; Tanaka, PY; Trabasso, P; Urakawa, P; Zanichelli, MA | 1 |
| Cheng, CJ; Chou, CH; Lin, CS; Lin, SH | 1 |
| Agarwal, N; Agarwal, S; Arya, SC; Solanki, BS | 1 |
| Afonso, MR; Albertoni, Ade C; Arkader, R; Cabral, EA; da Silva, DC; de Araujo, OR; Diegues, AR; Louzada, ME | 1 |
| Hoda, MQ; Hussein, K; Manasia, R; Salahuddin, N; Samad, A; Siddiqui, S; Zafar, A | 1 |
| Aron, DC; Bonomo, RA; Capitano, B; Donskey, CJ; Linden, PK; Muto, CA; Ndirangu, M; Paterson, DL; Potoski, BA | 1 |
| Bai, YL; Chen, BY; Chu, YZ; Li, JB; Li, LY; Wan, JH; Wang, Q; Wang, X; Zhang, JP; Zhao, ZM | 1 |
| Klaustermeyer, W; Lam, A; Randhawa, I | 1 |
| Iguchi, A; Kaneda, M; Kobayashi, K; Kobayashi, R; Sato, T; Yasuda, K | 1 |
| Hazar, V; Karasu, GT; Ogunc, D; Uygun, V; Yesilipek, A | 1 |
| Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
| Bastús, R; Cirera, L; Estany, C; Estrada, C; Garau, J; Gómez, I; Gómez, L; Márquez, M; Martí, JM; Quintana, S | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Barshikar, S; Baylor, AE; Dolman, HS; Glowniak, J; Hong, K; Lavery, T; Nailor, M; Singla, R; Stassinopoulus, J; Tyburski, JG; Wilson, RF; Zimmerman, LH | 1 |
| Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Kaneda, M; Ohshima, J; Suzuki, D | 1 |
| Bosso, JA; Church, EC; Mauldin, PD | 1 |
| Altunsoy, A; Aypak, C; Azap, A; Balık, I; Ergönül, Ö | 1 |
| Cotton, F; De Backer, D; Jacobs, F; Macours, P; Seyler, L; Taccone, FS; Vincent, JL | 1 |
| Landau, Z; Miller, EB; Shichmanter, R; Shtalrid, M | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Kronenberg, A; Mühlemann, K; Pannatier, A; Plüss-Suard, C; Ruffieux, C; Zanetti, G | 1 |
| Homann, C; Knudsen, JD; Moser, C; Novovic, S; Olsen, H; Semb, S | 1 |
| Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH | 1 |
| Bhargava, A; Bheemreddy, S; Chopra, T; Dhar, S; Gudur, UM; Hayakawa, K; Kaye, KS; Lephart, PR; Marchaim, D; Mynatt, RP; Sunkara, B; Zhao, JJ | 1 |
| Faoagali, J; Gallagher, JE; George, N; Gidding, HF; Ginn, AN; Iredell, JR; Lipman, J; O'Driscoll, JS; O'Toole, BI; Partridge, SR; Perri, RA; Wiklendt, AM | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Aziz, MN; Desa, MN; Idris, SN; Taib, NM | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H | 1 |
| Hashiguchi, R; Komatsu, M; Matsuyama, S; Moronaga, Y; Nagahara, C; Oshiro, Y; Sameshima, I; Takeyama, H; Tottori, N; Yaita, K; Yamaguchi, Y | 1 |
| Browning, R; Darwiche, K; Freitag, L; Kioumis, I; Li, Q; Parrish, S; Petridis, D; Porpodis, K; Ritzoulis, C; Spyratos, D; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Finnegan, PM; Hand, S; Linneman, TW; McDonald, JR; Moenster, RP; Thomas, Z | 1 |
| Apisarnthanarak, A; Lye, DC; Ng, TM; Teng, CB | 1 |
| Feng, X; He, L; He, Y; Li, C; Liu, H; Liu, X; Ruan, Y; Wu, X; Zhang, Y | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Doi, Y; Qureshi, ZA | 1 |
| Singh, HL; Singh, RM | 1 |
| Birch, A; Della Vecchia, BJ; Dupree, L; Gomes, DM; Jankowski, CA; Kraemer, DF; Smotherman, C | 1 |
| Chu, X; Guo, YY; Liu, QZ; Shen, LM; Wang, J; Zhang, CL | 1 |
| Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
| Chan, MC; Chang, FY; Lee, Y; Lin, JC; Lin, TY; Yang, YS; Yeh, KM | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Mills, JC | 1 |
| Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D; Yasuda, K | 1 |
| Bae, EY; Cho, B; Chung, NG; Han, SB; Jeong, DC; Jung, SW; Kang, JH; Kim, HK; Lee, DG; Lee, JW; Park, YJ | 1 |
| Duffy, A; Gilmore, S; Heil, EL; Nguyen, AD; Patel, NK | 1 |
| Berrazeg, M; Broutin, I; Fournier, D; Jeannot, K; Loeffert, S; Ntsogo Enguéné, VY; Plésiat, P | 1 |
| Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
| Aamir, M; Abrol, P; Punia, H; Sharma, D | 1 |
| Fowler, RC; Geyer, CN; Hanson, ND; Hawkey, P; Johnson, JR; Johnston, B; Weissman, SJ | 1 |
| Bork, JT; D'Angelo, RG; Heil, EL; Johnson, JK | 1 |
| Cohen, H; Peyko, V; Smalley, S | 1 |
| Hammond, DA; Lusardi, K; Meena, NK; Painter, JT; Smith, MN | 1 |
| Gustinetti, G; Mikulska, M | 1 |
| Chen, TL; Chuang, MF; Huang, WC; Kuo, SC; Lauderdale, TL; Lee, Y; Tseng, KC; Yang, YS | 1 |
| Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
| Chen, J; Kong, C; Zhang, Y; Zhu, L; Zou, X | 1 |
| Monogue, ML; Nicolau, DP | 1 |
| Burgess, DR; Burgess, DS; Cox, JN; Martin, CA; Rutter, WC | 1 |
| Evans, R; Hussain, T; Karino, S; Kaye, KS; Koons, J; Koppula, S; Martin, ET; Murray, KP; Mynatt, RP; Navalkele, B; Nishan, B; Perry, W; Pervaiz, A; Pogue, JM; Rybak, MJ; Salim, M; Shaikh, H; Solanki, S; Tashtoush, N | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Gao, L; Li, Y; Lyu, Y | 1 |
| Rodriguez-Bano, J; Tamma, PD | 1 |
| Li, B; Li, L; Peters, BM; Shirtliff, ME; Xie, J; Xu, Z; Yu, G | 1 |
| LeCleir, LK; Pettit, RS | 1 |
| Basu, A; Borse, RH; Gaultney, J; Kauf, TL; Medic, G; Miller, B; Prabhu, VS; Sen, SS | 1 |
| Hincapie Castillo, J; Jeon, N; Klinker, KP; Staley, B; Winterstein, AG | 1 |
| Ahir, H; Foo, J; Merchant, S; Prabhu, V; Sarpong, E | 1 |
| Falagas, ME; Kofteridis, DP; Maraki, S; Mavromanolaki, VE; Perdikis, D; Samonis, G; Vardakas, KZ | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND | 1 |
| Burgess, DR; Burgess, DS; Cotner, SE; Martin, CA; Rutter, WC; Wallace, KL | 1 |
| Anderson, KT; Kao, LS; Lally, KP; Mueck, KM; Putnam, LR; Tsao, K | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Alfandari, S; Bertrand, X; Dumartin, C; Gauzit, R; Gbaguidi-Haore, H; Muller, A; Péfau, M; Rogues, AM | 1 |
| Amit, O; Avivi, I; Ben-Ami, R; Halavy, Y; Katchman, E; Kor, S; Paran, Y; Ram, R; Yachini, B | 1 |
| Hao, D; Hu, Z; Liu, X; Sun, T; Tian, H; Wang, T; Wang, X | 1 |
| Avendano, EE; Chan, J; Merchant, S; Puzniak, L; Raman, G | 1 |
| Ejaz, A; Ejaz, H; Javed, H; Saleem, R; Younas, S; Zafar, A | 1 |
| Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R | 1 |
| DePestel, DD; DeRyke, CA; Gupta, V; Merchant, S; Murray, J; Puzniak, L; Srinivasan, A; Ye, G | 1 |
| Chen, GJ; Chen, WT; Foo, J; Morel, C; Pan, SC; Wang, JT | 1 |
| Bernard, S; Lee, K; Pakyz, A; Stevens, M; Vaughan, D | 1 |
| Hoban, DJ; Lob, SH; Motyl, MR; Sahm, DF; Young, K | 1 |
| Andreasen, MR; Hansen, KH; Jelsbak, L; Pedersen, MS; Schønning, K; Westh, H | 1 |
| Bardonneau, G; Biais, M; Carrié, C; Gruson, D; Ouattara, A; Pereira, B; Petit, L | 1 |
| Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A | 1 |
| Carvalhaes, CG; Castanheira, M; Doyle, TB; Sader, HS; Streit, JM | 1 |
| Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A | 1 |
| Fink, G; Horn, S; Kern, WV | 1 |
| Garello, P; Livermore, DM; Mushtaq, S; Vickers, A; Woodford, N | 1 |
| Brown, M; Gamage, HKAH; Ginn, AN; Holmes, A; Iredell, JR; Kabir, M; Nayyar, V; Partridge, SR; Paulsen, IT; Roychoudhry, B; Seppelt, I; Tetu, SG; Thomas, L; Venturini, C | 1 |
| Beer, JH; Camenzind, D; Tarnutzer, AA; Zimmermann, P | 1 |
| Carvalhaes, CG; Castanheira, M; Sader, HS; Shortridge, D | 1 |
| Aitken, SL; Heil, EL; Monogue, ML; Pogue, JM | 1 |
| Brateanu, A; Imrey, PB; Le, P; Navaneethan, SD; Pallotta, AM; Patel, P; Rastogi, R; Rothberg, MB; Yu, PC | 1 |
| Chen, WT; DeRyke, CA; Kazmierczak, KM; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Anzinger, FX; Friess, H; Neumann, PA; Novotny, A; Reischl, S; Rothe, K; Stöss, C; Wilhelm, D | 1 |
| Gillani, SW; Hussain, MW; Mahmood, RK; Rathore, HA; Saeed, MW; Vippadapu, P | 1 |
| Castanheira, M; Chen, WT; Pfaller, M; Shortridge, D; Streit, J; Tulloch, M | 1 |
| Ben-Zvi, H; Fanous, E; Herscovici, T; Kaplan, E; Livni, G; Mor, M; Schiller, O; Vardi, Y | 1 |
| Haines, RR; Hammer, KA; Putsathit, P; Tai, AS | 1 |
| Apiwattanakul, N; Boonsathorn, S; Chaisavaneeyakorn, S; Prasopchoknapaporn, P; Techasaensiri, C | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D | 1 |
| Asano, Y; Fukumoto, K; Ito, Y; Kaneko, M; Masuda, Y; Miura, M; Moriyama, C; Nakamura, T; Sakai, K; Sawachika, H; Shikata, H; Shinomiya, H; Ujike, A; Utsunomiya, Y; Yamamoto, H | 1 |
| Andereck, J; Casey, JD; Dear, ML; Dennis, B; Lloyd, BD; Nelson, G; Qian, ET; Rice, TW; Seitz, K; Self, WH; Semler, MW; Siemann, J; Siew, ED; Stollings, J; Wang, L; Wrenn, J; Wright, A; Wright, P | 1 |
| Bercot, B; Bernier, J; Bleibtreu, A; Chaibi, K; Contejean, A; Cuzon, G; Delory, T; El Alaoui, F; Escaut, L; Joseph, A; Lafaurie, M; Maillard, A; Molina, JM; Paccoud, O; Poupet, H; Robert, J; Surgers, L; Tankovic, J; Villa, A | 1 |
| Casey, JD; Qian, ET; Rice, TW; Semler, MW; Stollings, JL; Wang, L | 1 |
| Bahrs, C; Bartonickova, L; Burgmann, H; Hagel, S; Paulussen, E; Pletz, MW; Schneider, L; Starzengruber, P; Tobudic, S | 1 |
12 review(s) available for cephalosporin c and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
Topics: Abdomen; Abdominal Abscess; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Surgical Wound Infection; Ticarcillin | 2000 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefepime; Ceftazidime; Cephalosporins; Clavulanic Acids; Cystic Fibrosis; Disease Progression; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 2013 |
Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cholangitis; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Kidney; Liver Abscess, Pyogenic; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Escherichia coli sequence type 131: epidemiology and challenges in treatment.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Cystitis; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; United States | 2014 |
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Gram-Negative Aerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Bloodstream infections in neutropenic cancer patients: A practical update.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Disease Management; Drug Resistance, Bacterial; Febrile Neutropenia; Fluoroquinolones; Gram-Negative Bacteria; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pre-Exposure Prophylaxis; Risk Factors | 2016 |
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Cefepime; Cephalosporins; Cephamycins; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2017 |
Risk factors for hospitalized patients with resistant or multidrug-resistant
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cephalosporins; Critical Care; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Risk Factors; Vancomycin | 2018 |
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam | 2020 |
A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Tazobactam; Urinary Tract Infections | 2022 |
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2022 |
15 trial(s) available for cephalosporin c and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Consumer Product Safety; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Population; Treatment Failure; Ventilators, Mechanical | 1998 |
Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Topics: Aged; Amikacin; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Drug Therapy, Combination; Female; Hospital Mortality; Hospitals, Teaching; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Spain; Survival Analysis; Treatment Outcome | 2001 |
A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Fever; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome | 2006 |
A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefozopran; Ceftazidime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Prospective Studies; Survival Rate | 2008 |
Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.
Topics: Adolescent; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Infant; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2009 |
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Fever of Unknown Origin; Humans; Incidence; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Poisoning; Prospective Studies; Treatment Outcome; Young Adult | 2010 |
Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cefozopran; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Male; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2011 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; Cephalosporins; Ciprofloxacin; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
Prophylactic first-line antibiotics reduce infectious fever and shorten hospital stay during chemotherapy-induced agranulocytosis in childhood acute myeloid leukemia.
Topics: Adolescent; Agranulocytosis; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cefepime; Cephalosporins; Child; Child, Preschool; Female; Fever; Humans; Infection Control; Length of Stay; Leukemia, Myeloid, Acute; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Vancomycin | 2014 |
Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Young Adult | 2015 |
A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Fever; Humans; India; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tertiary Care Centers; Treatment Outcome | 2016 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Cephalosporins; Febrile Neutropenia; Female; Fever; Hematologic Neoplasms; Humans; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2018 |
Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Kidney; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies | 2023 |
111 other study(ies) available for cephalosporin c and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
Topics: Abdominal Abscess; Amino Acid Sequence; Ampicillin; Animals; Base Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Cephalosporins; DNA, Bacterial; Drug Therapy, Combination; Escherichia coli; Klebsiella Infections; Klebsiella pneumoniae; Molecular Biology; Molecular Sequence Data; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; R Factors; Rats; Sulbactam | 1996 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
Topics: beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Probability | 2003 |
In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
Topics: Bacteria; Bacterial Infections; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Gram-Negative Bacteria; Humans; In Vitro Techniques; Ireland; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors; United Kingdom | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance.
Topics: Anti-Bacterial Agents; Argentina; Cephalosporin Resistance; Cephalosporins; Cross Infection; Drug Prescriptions; Drug Utilization; Humans; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2004 |
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.
Topics: Aged; Anti-Bacterial Agents; Cefotaxime; Cephalosporins; Clostridioides difficile; Diarrhea; Drug Prescriptions; Drug Resistance; Drug Utilization; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Public Policy; Retrospective Studies; United Kingdom | 2004 |
Continuous infusion beta-lactams for intensive care unit pulmonary infections.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Drug Combinations; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Infusions, Intravenous; Intensive Care Units; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; United States | 2005 |
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms.
Topics: beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Drug Therapy, Combination; Escherichia coli; Infusion Pumps; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Utilization Review; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Male; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Mupirocin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolones; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Antibiotic-induced enterococcal expansion in the mouse intestine occurs throughout the small bowel and correlates poorly with suppression of competing flora.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Clavulanic Acids; Clindamycin; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Escherichia coli; Green Fluorescent Proteins; Intestine, Small; Metronidazole; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ticarcillin | 2006 |
Evaluating broad-spectrum antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cephalosporins; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2006 |
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Brazil; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infant; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prospective Studies; Risk Factors | 2007 |
Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
Topics: Anti-Bacterial Agents; Brain; Bronchiectasis; Cefazolin; Cefepime; Cephalosporins; Electroencephalography; Epilepsies, Myoclonic; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Molecular Structure; Penicillanic Acid; Penicillin G; Peritoneal Dialysis, Continuous Ambulatory; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Hospitals, Urban; Humans; India; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2007 |
Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Time Factors | 2007 |
Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Developing Countries; Drug Prescriptions; Drug Resistance, Microbial; Drug Utilization Review; Humans; Imipenem; Intensive Care Units; Medical Order Entry Systems; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Program Development; Vancomycin | 2007 |
Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
Topics: Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Culture Media; Enterococcus; Female; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum; Vancomycin Resistance | 2008 |
[Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli].
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Humans; Intestines; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies | 2007 |
Cephalosporin induced toxic epidermal necrolysis and subsequent penicillin drug exanthem.
Topics: Aged, 80 and over; Cephalosporins; Drug Hypersensitivity; Exanthema; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Stevens-Johnson Syndrome | 2008 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained.
Topics: Abdominal Abscess; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofloxacin; Exudates and Transudates; Female; Fluconazole; Humans; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Suction; Treatment Outcome; Vancomycin | 2011 |
Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Formularies, Hospital as Topic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Cost Savings; Cross Infection; Drug Costs; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Escherichia; Health Policy; Hospitals; Humans; Imipenem; Klebsiella; Meropenem; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Staphylococcus aureus; Teicoplanin; Thienamycins; Turkey; Vancomycin | 2011 |
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Female; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2011 |
[Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward].
Topics: Adult; Aged; Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Fever; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Treatment Outcome | 2010 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Utilization; Health Policy; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Policy; Pseudomonas aeruginosa; Switzerland; Thienamycins; Time Factors | 2012 |
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Denmark; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Meropenem; Middle Aged; Mycoses; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2012 |
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cefuroxime; Cephalosporins; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2012 |
The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Nasopharynx; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Survival Rate | 2012 |
Antimicrobial susceptibility pattern and distribution of exoU and exoS in clinical isolates of Pseudomonas aeruginosa at a Malaysian hospital.
Topics: ADP Ribose Transferases; Adult; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Cefepime; Ceftazidime; Cephalosporins; Chi-Square Distribution; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Female; Gentamicins; Hospitals; Humans; Malaysia; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.
Topics: Aerosols; Ampicillin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Chemistry, Pharmaceutical; Equipment Design; Meropenem; Nebulizers and Vaporizers; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2013 |
Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Diabetes Complications; Drug Therapy, Combination; Humans; Incidence; Middle Aged; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2014 |
A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Central Venous Catheters; Cephalosporins; Coinfection; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Respiratory Tract Infections; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Comparative evaluation of six phenotypic methods for detecting extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Cefepime; Cefotaxime; Ceftazidime; Cephalosporins; Enterobacteriaceae; False Negative Reactions; False Positive Reactions; Female; Humans; India; Male; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests | 2014 |
Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Treatment Outcome; Vancomycin | 2014 |
Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporin Resistance; Cephalosporins; Child; Child, Preschool; China; Ciprofloxacin; Dysentery, Bacillary; Female; Galanin; Genes, Bacterial; Genotype; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Shigella; Substance P; Virulence | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Clinical manifestations and prognostic factors of Morganella morganii bacteremia.
Topics: Age Factors; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Morganella morganii; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Taiwan | 2015 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefepime; Cephalosporins; Child; Escherichia coli; Escherichia coli Infections; Febrile Neutropenia; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
A single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Leukemia; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Post-Exposure Prophylaxis; Random Allocation; Retrospective Studies; Risk Factors; Young Adult | 2016 |
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Topics: Adaptation, Physiological; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Gene Expression; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Structure, Secondary; Protein Structure, Tertiary; Pseudomonas aeruginosa; Tazobactam; Ticarcillin | 2015 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Evaluation of CTX-M steady-state mRNA, mRNA half-life and protein production in various STs of Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Disk Diffusion Antimicrobial Tests; Escherichia coli; Genotype; Humans; Immunoblotting; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA, Messenger; Tazobactam | 2016 |
Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Vancomycin | 2017 |
Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Arkansas; Cefepime; Cephalosporins; Critical Illness; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2016 |
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Taiwan; Thienamycins | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
[Study on drug sensitivity against Comamonas testosteroni by Kirby-Bauer disk diffusion method].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Comamonas testosteroni; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2016 |
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Colistin; Culture Media; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tobramycin; Treatment Outcome | 2016 |
Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Kidney; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2017 |
Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Length of Stay; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Retrospective Studies; Risk; Severity of Illness Index; Vancomycin | 2017 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Trends in Drug Resistance of
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Cefepime; Cefoperazone; Ceftazidime; Cephalosporins; China; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2017 |
Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001-2015.
Topics: Amikacin; Anti-Bacterial Agents; Blood; Carbapenems; Ceftazidime; Cephalosporins; China; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacter; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sputum; Urinary Tract | 2017 |
Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
Topics: Acute Kidney Injury; Adolescent; Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tobramycin; Vancomycin | 2017 |
Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Hospitalization; Humans; Middle Aged; Monte Carlo Method; Mortality; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; United States; Urinary Tract Infections | 2017 |
Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Assessment; Vancomycin; Young Adult | 2017 |
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Cephalosporins; Clinical Protocols; Drug Combinations; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections; Male; Metronidazole; Models, Econometric; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Tazobactam; United Kingdom | 2017 |
In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Child; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Greece; Hospitals, University; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tigecycline | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2017 |
Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Kidney; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Does compliance with antibiotic prophylaxis in pediatric simple appendicitis matter?
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Appendectomy; Appendicitis; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; Guideline Adherence; Humans; Infant; Infant, Newborn; Logistic Models; Male; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Preoperative Care; Retrospective Studies; Surgical Wound Infection; Treatment Outcome | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Gene Expression; Hospitalization; Humans; Isoenzymes; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Plasmids; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tazobactam; United States | 2018 |
Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Fluoroquinolones; France; Glycopeptides; Guidelines as Topic; Hospitals; Humans; Intensive Care Units; Logistic Models; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Prescriptions; Probability; Retrospective Studies | 2018 |
[Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015]
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Cross Infection; Drug Resistance; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Retrospective Studies; Thienamycins | 2016 |
AmpC beta-lactamases in Klebsiella pneumoniae: An emerging threat to the paediatric patients.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefoperazone; Cefoxitin; Cephalosporins; Child; Child, Preschool; Ciprofloxacin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals, Pediatric; Humans; Imipenem; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Pakistan; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2018 |
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing | 2019 |
A Combination Antibiogram Evaluation for
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Hospitals; Humans; Intensive Care Units; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; United States | 2019 |
Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Gram-Negative Bacteria; Humans; Middle Aged; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Taiwan; Tazobactam; Time Factors; Treatment Outcome; Urinary Tract Infections; Young Adult | 2019 |
Adequacy of empiric gram-negative coverage for septic patients at an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Gram-Negative Bacteria; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Shock, Septic; Virginia; Young Adult | 2019 |
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
Topics: Abdomen; Adult; Aged; Ceftazidime; Cephalosporins; Female; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Respiratory System; Tazobactam; United States; Urinary Tract | 2020 |
Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Sequence Analysis, DNA | 2019 |
Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically ill patients with hospital or ventilator-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cephalosporins; Critical Illness; Cross Infection; Enterobacter; Family Characteristics; Female; Hospitals; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Retrospective Studies; Ventilators, Mechanical | 2020 |
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam; United States; Whole Genome Sequencing | 2021 |
[Antibiotic stewardship - recent developments].
Topics: Aminoglycosides; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactams; Cephalosporins; Fluoroquinolones; Germany; Humans; Neutropenia; Piperacillin, Tazobactam Drug Combination; Urinary Tract Infections | 2020 |
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2021 |
Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients.
Topics: Adult; Animals; Antimicrobial Stewardship; Cephalosporins; Critical Illness; Enterobacteriaceae; Female; Humans; Male; Microbiota; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S | 2021 |
Negative myoclonus as the leading symptom in acute cefepime neurotoxicity.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Brain Ischemia; Cefepime; Cephalosporins; Female; Humans; Myoclonus; Piperacillin, Tazobactam Drug Combination; Stroke | 2021 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.
Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Imipenem; Jupiter; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
The role of tazobactam-based combinations for the management of infections due to extended-spectrum β-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Drug Combinations; Enterobacteriaceae Infections; Humans; Pharmacists; Piperacillin, Tazobactam Drug Combination; Societies, Medical; Tazobactam; United States | 2021 |
Association of antibiotic use and acute kidney injury in patients hospitalized with community-acquired pneumonia.
Topics: Acute Kidney Injury; Adolescent; Adult; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Female; Humans; Macrolides; Male; Piperacillin, Tazobactam Drug Combination; Pneumonia; Retrospective Studies; Vancomycin | 2022 |
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Intensive Care Units; Meropenem; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tazobactam; Thailand | 2022 |
[The importance of microbiological results for the treatment of complicated appendicitis-a monocentric case-control study].
Topics: Ampicillin; Anti-Bacterial Agents; Appendicitis; Case-Control Studies; Cephalosporins; Escherichia coli; Humans; Metronidazole; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Sulbactam | 2022 |
Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Meropenem; Microbial Sensitivity Tests; New Zealand; Penicillanic Acid; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2022 |
Definitive antibiotic treatment with a third-generation cephalosporin and with piperacillin-tazobactam worked well for some children with Serratia bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Child; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Serratia; Thrombocytopenia | 2022 |
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Pediatric drug utilization evaluation of cefepime and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Child; Drug Utilization Review; Humans; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2022 |
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2023 |
Isolation of OXA-48-like carbapenemase-producing Escherichia coli susceptible to piperacillin/tazobactam in a Japanese patient without a history of travel abroad.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; East Asian People; Escherichia coli; Female; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination | 2023 |
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2023 |
Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Coma; Critical Illness; Delirium; Drug Therapy, Combination; Humans; Piperacillin, Tazobactam Drug Combination | 2023 |
Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cohort Studies; Escherichia coli; Escherichia coli Infections; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolones; Retrospective Studies; Sulbactam | 2023 |